Ultragenyx Pharmaceutical (RARE)

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.

的Ultragenyx Pharmaceutical Inc. Common Stock（RARE）股票的价格今天是，自市场开启。该公司市值为$20.87亿，日交易量为股。前一交易日收盘价为 。

您准备好开始了吗？按照以下步骤操作，或阅读我们关于在Kraken上从10美元起购买Ultragenyx Pharmaceutical股票的指南。